Drug Trial Radar · NCT04238195
A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Mar 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jan 19, 2020
Primary completion
Feb 26, 2020
Study completion Feb 26, 2020
Sponsor
- Lead sponsor
- Spero TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Celerion
- First posted
- Jan 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind (with respect to Tebipenem pivoxil hydrobromide \[TBPM-PI-HBr\]/placebo only), placebo- and active-control, single-dose, 4-way crossover study that will enroll 24 healthy adult male and female subjects. There will be a washout period of at least 7 days between dosing in each period and each subject will receive all 4 treatments over 4 periods in a crossover study design.
Conditions
- TQT Study
Interventions
Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + PlaceboDrug
Treatment A: Subjects receive TBPM-PI-HBr + matching Placebo.
Moxifloxacin 400mgDrug
Treatment D: Subjects receive 1 400 mg tablet of moxifloxacin administered in an open label manner.
Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)Other
Treatment C: Subjects receive TBPM-PI-HBr matching placebo.
Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)Drug
Treatment B: Subjects receive TBPM-PI-HBr.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of a single therapeutic and supratherapeutic dose of TBPM-PI-HBr on the heart rate corrected QT interval (QTc) by assessing concentration-QT (C-QT) relationship using exposure-response modeling.Time frame: Pre-dose through 24 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.